Development FDA Approval Generic Pharmaceutical Insulin 
Pharmaceutical Technology
DECEMBER 22, 2022
The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. billion to expedite research and development (R&D) for infectious diseases in lower-income countries. Innovation.
XTalks
AUGUST 2, 2023
is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.
Expert insights. Personalized for you.
130 
Let's personalize your content